Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's DiseaseStephen Salloway, H. Robert Brashear, Reisa A. Sperling et al.|New England Journal of Medicine|2014Cited by 2k
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysisReisa A. Sperling, Michael Grundman, Stephen Salloway et al.|The Lancet Neurology|2012Cited by 510
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer diseaseStephen Salloway, Reisa A. Sperling, Ron Keren et al.|Neurology|2011Cited by 255
Amyloid-β <sup>11</sup> C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trialsEnchi Liu, Arthur Spirling, James McGowan et al.|Neurology|2015Cited by 152
Cognitive and Neural Effects of Vision‐Based Speed‐of‐Processing Training in Older Adults with Amnestic Mild Cognitive Impairment: A Pilot StudyFeng Lin, Duje Tadin, Kathi L. Heffner et al.|Journal of the American Geriatrics Society|2016Cited by 114